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ABSTRACT
A review is made of the indications of ultrasonographic con-
trast enhancement as applied to conventional ultrasonography
and endocopic ultrasonography (EUS) as opposed to the use of
EUS-sonoelastography today.
Key words: Ultrasonographic contrast media. Contrast-enhan-
ced echoendoscopy. Elastography. Endoscopic sonoelastography.
Echoendoscopy with sonoelastography. Neuroendocrine tumors.
Pancreatic cancer. Chronic pancreatitis.
INTRODUCTION
Gastrointestinal real-time, gray-scale ultrasonography
(US) has reached high resolution, performance, and sen-
sitivity in the study of biliary, hepatosplenic, pancreatic,
and even gastrointestinal (GI) tract conditions. It was
then supplemented by color Doppler (CD) and power
Doppler or color angiosonography, and more recently by
contrast-enhancement (CE) (Gómez, 2007) and three di-
mensions (3-D) (Muñoz, 2007) in our country (1).
The same thing happened to echoendoscopy or endo-
scopic ultrasonography (EUS). Color, sonoelastography,
and contrast media have provided US with a new diag-
nostic and most particularly therapeutic dimension (2).
Color has made it possible to better study blood ves-
sels (portal hypertension and growths).
Sonoelastography and contrast agents have attempted
to improve diagnosis and avoid histological studies using
fine needle aspiration puncture (FNA) (virtual biopsy)
(Figs. 1 and 2).
However, what is the future of CE as applied to ultra-
sonography (CE-US) or endoscopic ultrasonography (CE-
EUS), including intraoperative ultrasonography (CE-IUS)?
The use of CE in these three diagnostic scenarios —US,
EUS, IUS— is discussed below.
FACT AND FUTURE OF CE-US
The following indications are now a fact:
– Characterization, delimitation, and detection in the
liver of hepatic masses in over 90% of patients (3-
5); detection of masses in the spleen and pancreas
(6).
– Diagnosis of portal hypertension and portal throm-
bosis (100%), even if malignant (94%).
– Differentiation between benign and malignant le-
sions in a percentage above 95% (7).
– Study of GI tract microcirculation: thrombosis, is-
chemia (8), and inflammatory bowel disease (IBD) (9).
– Ablative therapy control.
The future likely lies in these last two fields:
– Gene therapy
– Functional studies.
FACT AND FUTURE OF CE-EUS
There are no conclusive studies regarding the use of
CE-EUS for adenopathies and the GI tract.
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In the study of pancreatic conditions using CE-EUS
pancreatic cancer (PC) detection —including smaller tu-
mors (11)— is now a fact (10), but the differential diag-
nosis between adenocarcinoma and chronic nodular pan-
creatitis remains problematic.
Endoscopic retrograde cholangiography (ERC) and
magnetic resonance cholangiography (MRC) have a sen-
sitivity nearing 85%, CT and EUS are above 90%, and
EUS-FNA reaches up to 95% (with a mean 86% that
boils down to 54% in the presence of chronic pancreati-
tis) with a specificity of almost 100%, whereas CE-EUS
has a sensitivity of 93% and a specificity of nearly 100%
(94%).
What about EUS sonoelastograhy?
Most published papers on pancreatic masses show
high sensitivity (87%) and moderate specificity in differ-
entiating benign from malignant lesions except for a re-
cent report of low sensitivity and specificity in the diag-
nosis of even adenocarcinoma (50%) that recommends
FNA.
Recent papers (12,13) in our country obtained a sensi-
tivity of 100% and a specificity of 78 and 85%. There-
fore, this test may well obtain false positive but no false
negative results, interestingly in contrast to EUS-FNA.
Neuroendocrine tumor (NET) detection with CE (Fig.
1) approaches 100% (14) (Giovanninni 7/8: 88%), and
the same occurs with NET metastases (15,16). Therefore,
it might be indicated for the detection of tumors in pa-
tients with multiple endocrine neoplasia (MEN) (small,
multiple tumors).
FACT AND FUTURE OF IUS AND CE-LAPUS
It has been shown in 60 patients that CE is more sensi-
tive that intraoperative US (IUS) for the detection of liver
metastases, and modifies the management and resection
with curative intent in 30% of patients (17).
Better results have also been obtained with CE-IUS
versus IUS in the detection of 20 cases of hepatocarcino-
ma (HC) on liver cirrhosis (18).
The use of CE will be crucial prior to liver resection
and probably pancreas resection in the future.
FUTURE-RELATED CONCLUSIONS
1. Detection of smaller HCs.
2. Ablative therapy control.
3. Detection of overlooked liver micrometastases,
particularly from colon cancer.
4. Study of intestinal microcirculation (inflamma-
tion, ischemia, thrombosis).
5. Smaller NETs. MEN?
6. Differential diagnosis of PC versus CP. Masses.
7. Contribution to liver and possibly pancreatic re-
section?
8. Gene therapy.
9. Gene therapy control.
10. Other, including functional studies, etc.
ADDENDUM
While CE is not licensed in some countries, its impact
has been demonstrated (diagnosis in 90% with modifica-
tion of patient management in 17.5 and 15.6%, and up to
30% with CE-IUS) (17,19,20), as well as its implementa-
tion cost-effectiveness.
Lacking ionizing radiation and with no renal toxicity
in over 23,000 patients (scarce morbidity, no mortality)
(21), the diagnostic information achieved is compara-
ble to that of CT and MRI (22); for some authors (23) it
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Fig. 1. Hypervascular neuroendocrine tumor (by courtesy of Dr. Die-
trich) (2).
Fig. 2. Pancreatic cancer sonoelastogram (by courtesy of Dr. Giovannini).
even has enthralling future indications in the diagnosis
and even treatment of digestive system conditions (24-
29).
Sonoelastography (16,30-34) must improve in the fu-
ture (2nd or 3rd generation) its sensitivity and specificity
for pancreatic tumors, adenopathies, and submucosal tu-
mors in order to compete with contrast media and FNA
(Tables I and II).
A novel option would combine sonoelastography and
contrast agents in the differential diagnosis between
chronic pancreatitis and pancreatic cancer (40) with a
gain in specificity and PPV (96%) (Table III).
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Table I. References overview
EUS-Sonoelastography
Giovannini (35) 2006: 24 pancreas g. (1 NET) S: 100% Sp: 67%
Giovannini (2) 2008: 121 P: 89.2% S: 80.6% Sp: 92.3% PPV: 93.3 NPV: 78%
Giovannini (36) 2009: 121 S: 92.3% Sp: 80%
Janssen, 2007: 73 20 PC and 2 NET P: 73.5 S: 93.8 Sp: 65.4% PPV: 51.7 NPV: 96.5
Deprez, 2007: 18 7 PC, 3 NET, 6 CP S: 100% Sp: 50% PPV: 77 NPV: 100
Saftoiu, 2007: 7 PC P: 84.4% S: 80% Sp: 91.7% PPV: 94.1 NPV: 73.7
Hirche (37) 2008: 70 c. 10 C. P: 45% S: 41% Sp: 53%
Quites previous papers 46 PC and 12 NET (100%)
Saftoiu (38) 2008: 32 PC, 11 CP, 3 P: 89.7% S: 91.4% Sp: 87.9% PPV: 88.9 NPV: 90.6
Iglesias (12) 2008: 80 c, 10 C P: 93.7% S: 100% Sp: 78.3%
Iglesias (13) 2009: 130 c, 20 C P: 94% S: 100% Sp: 85.5%
Iglesias (43) 2010: 86 c (49 CP) S: 100% Sp: 92.9% (6 NET)
Mean P: 81% S: 89% Sp: 76% PPV: 82% NPV: 89%
Table II. References overview
CE-EUS:
Hirooka 1998 37 c. (Albunex) S: 100% NET and 75% IPMT
Becker (39) 2001: 23 (Optison) S: 94% Sp: 100% PPV:100 NPV: 88%
Hocke (10) 2006: 86 CP (Sonovue) S: 91.1% Sp: 93.3%
Sakamoto (11) 2008: 156 PT (Levovist) S: 94.4%
Kitano 36 < 2 cm S: 83.3% vs. 50% CT
Carrara (14) 10 NET (Sonovue) S: 100%
Giovanninni 2009 (32) 7/8 NET (87.5%) S: 90.9% Sp: 88.8% PPV: 88.2 NPV: 91.4
(Sonovue)
Dietrich (24) 2008: 62 PP, 20 NET (100%) S: 92% Sp: 100%
(Levovist)
Napoleón (30) 2010: 35 c. 18 PC, 9 NET S: 89% Sp: 88% PPV: 89% NPV: 88%
(Sonovue) P: 88.5%
Xia (31) 2010: 43 growths S: 96.3% Sp: 100% PPV:100% NPV: 94%
P: 97.6%
Fusaroli (44) 2010: 90 c. 13 NET (85%) S: 96% Sp: 98%
(Sonovue)
Mean for all papers: S: 93% Sp: 94% PPV: 94% NPV: 90%
IPMT: S: 75%
PC: S: 91% Sp: 93%
NET: S: 95%
CE-US versus CE-EUS
Dietrich (2) 2007: 112 growths: 70 PC S: 90% Sp: 100% PPV: 100 NPV: 85.7
CE-US 42 pancreatic nodules S: 100% Sp: 90% P: 93.8%
Dietrich (24) 2008: 62 PC, 20 NET S: 92% Sp: 100%
CE-EUS (Levovist)
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CT + EUS recommended, as well as CA 19.9 measurement
Possibilities:






Diagnosis by 2nd-line imaging tests:
EUS-Sonoelastography <100%? S: 89% Sp: 76%
Contrasts (CE) 95% S: 92% Sp: 94%
EUS-FNA 90% S: 86% Sp: 97%
Contrasts vs. EUS-S? CE versus FNA
CE plus EUS-S
Staging and resectability:
EUS more than CT (2)
Non-resectability:
EUS-FNA if preoperative neoadjuvancy (41)
Modified and extended from references 2, 42, and 45. CP: chronic pancreatitis. PC: pancreatic cancer. NET: neuroendocrine tumor. C: control.
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